With increasing geopolitical disruptions and shifting trial strategies, India emerges as an attractive destination for early-stage clinical trials, …
With increasing geopolitical disruptions and shifting trial strategies, India emerges as an attractive destination for early-stage clinical trials, …
Acadia Pharmaceuticals advances its serotonin 5-HT₂A inverse agonist, remlifanserin (ACP-204), into the final phases of clinical testing as …
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) modernizes its clinical trial framework with major updates to …
Atalanta Therapeutics raises $97 million in Series B funding to accelerate RNA interference therapies into Phase 1 trials, …
Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
Sarepta Therapeutics reports encouraging Phase III trial data for Elevidys, its AAV-based gene therapy for Duchenne muscular dystrophy, …
Oncolytics Biotech discloses compelling new pelareorep combination data—in anal and pancreatic cancer cohorts—highlighting durable responses and tolerable safety …
Dogwood kicks off the Phase IIb study of Halneuron®, a non-opioid Nav1.7 inhibitor for chemotherapy-induced neuropathy—marking a critical …
The journal Nature identifies seven transformative technologies for 2025, with self-driving laboratories and advanced immunotherapies set to accelerate …
The European Medicines Agency approves GSK’s PD-1 inhibitor, Jemperli, in combination with chemotherapy as a first-line therapy for …
Already a subscriber? Log in